Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

por Lorenzen, S, Duyster, J, Lersch, C, von Delius, S, Hennig, M, Bredenkamp, R, Peschel, C, Lordick, F
Publicado 2005

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY

por Lorenz, K., Strüßmann, T., Trepel, M., Illerhaus, G., Pelz, H., Scholz, C., Duyster, J., Marks, R.
Publicado 2022

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation

por Sigl, M, Spoerl, S, Schnittger, S, Meissner, J, Rummelt, C, Peschel, C, Duyster, J, Ho, A D, von Bubnoff, N
Publicado 2013

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia

por Greil, C., Engelhardt, M., Ihorst, G., Duque-Afonso, J., Shoumariyeh, K., Bertz, H., Marks, R., Zeiser, R., Duyster, J., Finke, J., Wäsch, R.
Publicado 2020

Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia

por Greil, C., Engelhardt, M., Ihorst, G., Duque-Afonso, J., Shoumariyeh, K., Bertz, H., Marks, R., Zeiser, R., Duyster, J., Finke, J., Wäsch, R.
Publicado 2021

Depletion of STAT5 blocks TEL–SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice

por Sprissler, C, Belenki, D, Maurer, H, Aumann, K, Pfeifer, D, Klein, C, Müller, T A, Kissel, S, Hülsdünker, J, Alexandrovski, J, Brummer, T, Jumaa, H, Duyster, J, Dierks, C
Publicado 2014

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

por Lordick, F, Lorenzen, S, Stollfuss, J, Vehling-Kaiser, U, Kullmann, F, Hentrich, M, Zumschlinge, R, Dietzfelbinger, H, Thoedtmann, J, Hennig, M, Seroneit, T, Bredenkamp, R, Duyster, J, Peschel, C
Publicado 2005